fda warning glp-1 october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Regulators mostly silent on GLP-1

PlexusDx sources all compounded semaglutide from licensed 503A pharmacies, ensuring pharmaceutical-grade quality and safety across all 50 states, with no insurance required

In clinical trials of oral GLP1 medications, digestive symptoms were the most frequently reported side effects, occurring at rates similar to those seen with injections

ii) clinical (acne, hirsutism) or biochemical signs of hyperandrogenism

Volume III

A long-term retrospective study investigated the real-world effectiveness and safety of all the GLP-1 RAs available in Spain [68]

[DOI] [PubMed] [Google Scholar] 9.Rothkopf MM, Bilof ML, Haverstick LP, Nusbaum MJ